Biotechnology company developing new therapies for immune-mediated diseases and fibrosis.
Viridian Therapeutics, Inc. is a pioneering biotechnology company dedicated to developing transformative treatments for patients grappling with severe diseases. At the forefront of its innovative pipeline are VRDN-001, VRDN-002, and VRDN-003, each targeting the insulin-like growth factor 1 receptor (IGF-1R). VRDN-001, a humanized monoclonal antibody, is currently undergoing Phase 1/2 clinical trials for thyroid eye disease (TED). Concurrently, VRDN-002, another IGF-1R antibody, is advancing through Phase 1 clinical trials, while VRDN-003 is in development as a therapeutic antibody specifically designed for TED treatment.
Founded in 2006 and headquartered in Waltham, Massachusetts, Viridian Therapeutics, Inc. initially operated under the name Miragen Therapeutics, Inc., rebranding to its current identity in January 2021. The company's strategic evolution underscores its commitment to pioneering scientific advancements aimed at addressing significant medical challenges.
Viridian Therapeutics is driven by a mission to improve patient outcomes through rigorous research and development. By harnessing the potential of targeted therapies like IGF-1R antibodies, the company aims to provide effective treatment options for diseases with substantial unmet medical needs.
With a steadfast dedication to innovation and patient-centered care, Viridian Therapeutics continues to expand its scientific capabilities and explore new avenues in biotechnology. Through collaborative partnerships and cutting-edge research initiatives, the company remains poised to make a lasting impact in the field of therapeutic innovation.